Want to see GB:HIK full AI Analyst Report?
Hikma Pharmaceuticals (HIK) Ratios
Hikma Pharmaceuticals Ratios
GB:HIK's free cash flow for Q2 2026 was $46.61M. For the 2026 fiscal year, GB:HIK's free cash flow was decreased by $-121.00M and operating cash flow was $167.62M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.82 | 1.14 | 1.57 | 1.86 | 2.06 |
| Quick Ratio | 1.06 | 0.65 | 0.90 | 1.14 | 1.38 |
| Cash Ratio | 0.23 | 0.10 | 0.15 | 0.25 | 0.42 |
| Solvency Ratio | 0.21 | 0.19 | 0.15 | 0.16 | 0.30 |
| Operating Cash Flow Ratio | 0.25 | 0.29 | 0.45 | 0.49 | 0.63 |
| Short-Term Operating Cash Flow Coverage | 3.46 | 0.88 | 4.05 | 3.81 | 5.70 |
| Net Current Asset Value | $ -422.15M | $ -549.00M | $ -371.00M | $ -324.00M | $ 189.00M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.28 | 0.25 | 0.25 | 0.29 | 0.19 |
| Debt-to-Equity Ratio | 0.62 | 0.57 | 0.54 | 0.60 | 0.34 |
| Debt-to-Capital Ratio | 0.38 | 0.36 | 0.35 | 0.38 | 0.26 |
| Long-Term Debt-to-Capital Ratio | 0.36 | 0.21 | 0.31 | 0.33 | 0.21 |
| Financial Leverage Ratio | 2.19 | 2.22 | 2.13 | 2.09 | 1.78 |
| Debt Service Coverage Ratio | 3.41 | 0.97 | 2.92 | 2.05 | 4.06 |
| Interest Coverage Ratio | 5.36 | 8.16 | 4.08 | 7.68 | 15.57 |
| Debt to Market Cap | 0.34 | 0.22 | 0.22 | 0.29 | 0.11 |
| Interest Debt Per Share | 7.76 | 6.19 | 5.76 | 6.08 | 3.84 |
| Net Debt to EBITDA | 1.51 | 1.42 | 1.25 | 2.09 | 0.56 |
| Profitability Margins | |||||
| Gross Profit Margin | 43.03% | 45.25% | 48.94% | 50.26% | 50.96% |
| EBIT Margin | 18.12% | 19.44% | 21.53% | 11.60% | 23.50% |
| EBITDA Margin | 25.23% | 25.17% | 27.51% | 19.27% | 29.14% |
| Operating Profit Margin | 17.32% | 19.57% | 12.77% | 23.48% | 24.83% |
| Pretax Profit Margin | 15.82% | 14.55% | 9.77% | 9.26% | 21.31% |
| Net Profit Margin | 12.26% | 11.48% | 6.61% | 7.47% | 16.49% |
| Continuous Operations Profit Margin | 12.41% | 11.58% | 6.68% | 7.59% | 16.45% |
| Net Income Per EBT | 77.46% | 78.90% | 67.62% | 80.69% | 77.39% |
| EBT Per EBIT | 91.37% | 74.35% | 76.57% | 39.42% | 85.80% |
| Return on Assets (ROA) | 7.23% | 6.99% | 4.06% | 4.20% | 9.63% |
| Return on Equity (ROE) | 15.82% | 15.54% | 8.64% | 8.81% | 17.16% |
| Return on Capital Employed (ROCE) | 13.74% | 19.40% | 10.98% | 17.41% | 18.89% |
| Return on Invested Capital (ROIC) | 10.49% | 12.79% | 7.16% | 14.56% | 14.91% |
| Return on Tangible Assets | 9.12% | 9.03% | 5.31% | 5.62% | 12.10% |
| Earnings Yield | 8.92% | 6.46% | 3.75% | 4.48% | 6.07% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.10 | 3.46 | 3.64 | 3.24 | 3.27 |
| Payables Turnover | 2.67 | 4.78 | 4.75 | 4.30 | 4.78 |
| Inventory Turnover | 1.72 | 1.74 | 1.65 | 1.61 | 1.80 |
| Fixed Asset Turnover | 2.31 | 2.36 | 2.52 | 2.33 | 2.23 |
| Asset Turnover | 0.59 | 0.61 | 0.61 | 0.56 | 0.58 |
| Working Capital Turnover Ratio | 4.54 | 5.98 | 3.42 | 2.52 | 2.59 |
| Cash Conversion Cycle | 192.47 | 239.53 | 244.88 | 254.07 | 237.89 |
| Days of Sales Outstanding | 117.64 | 105.64 | 100.17 | 112.68 | 111.66 |
| Days of Inventory Outstanding | 211.65 | 210.22 | 221.54 | 226.23 | 202.62 |
| Days of Payables Outstanding | 136.83 | 76.33 | 76.83 | 84.84 | 76.38 |
| Operating Cycle | 329.30 | 315.85 | 321.70 | 338.91 | 314.27 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.66 | 2.53 | 2.73 | 2.37 | 2.76 |
| Free Cash Flow Per Share | 0.75 | 1.79 | 1.97 | 1.75 | 2.13 |
| Dividend Paid and CapEx Coverage Ratio | 0.94 | 1.66 | 1.99 | 2.02 | 2.41 |
| Capital Expenditure Coverage Ratio | 1.82 | 3.42 | 3.60 | 3.84 | 4.40 |
| Operating Cash Flow Coverage Ratio | 0.23 | 0.43 | 0.51 | 0.41 | 0.75 |
| Operating Cash Flow to Sales Ratio | 0.11 | 0.18 | 0.21 | 0.21 | 0.25 |
| Free Cash Flow Yield | 3.60% | 7.18% | 8.67% | 9.34% | 7.11% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 11.21 | 15.49 | 26.65 | 22.32 | 16.48 |
| Price-to-Sales (P/S) Ratio | 1.37 | 1.78 | 1.76 | 1.67 | 2.72 |
| Price-to-Book (P/B) Ratio | 1.77 | 2.41 | 2.30 | 1.97 | 2.83 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 27.81 | 13.93 | 11.54 | 10.71 | 14.07 |
| Price-to-Operating Cash Flow Ratio | 12.55 | 9.86 | 8.33 | 7.92 | 10.87 |
| Price-to-Earnings Growth (PEG) Ratio | 0.72 | 0.17 | 22.39 | -0.41 | -30.15 |
| Enterprise Value Multiple | 6.95 | 8.49 | 7.65 | 10.74 | 9.89 |
| Enterprise Value | 5.88B | 6.68B | 6.05B | 5.21B | 7.36B |
| EV to EBITDA | 6.95 | 8.49 | 7.65 | 10.74 | 9.89 |
| EV to Sales | 1.75 | 2.14 | 2.10 | 2.07 | 2.88 |
| EV to Free Cash Flow | 35.53 | 16.74 | 13.78 | 13.29 | 14.92 |
| EV to Operating Cash Flow | 16.03 | 11.84 | 9.95 | 9.83 | 11.53 |
| Tangible Book Value Per Share | 6.51 | 5.22 | 4.99 | 4.58 | 6.82 |
| Shareholders’ Equity Per Share | 11.76 | 10.36 | 9.88 | 9.54 | 10.62 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.22 | 0.20 | 0.32 | 0.18 | 0.23 |
| Revenue Per Share | 15.18 | 14.02 | 12.93 | 11.25 | 11.05 |
| Net Income Per Share | 1.86 | 1.61 | 0.85 | 0.84 | 1.82 |
| Tax Burden | 0.77 | 0.79 | 0.68 | 0.81 | 0.77 |
| Interest Burden | 0.87 | 0.75 | 0.45 | 0.80 | 0.91 |
| Research & Development to Revenue | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 |
| SG&A to Revenue | 0.17 | 0.18 | 0.22 | 0.20 | 0.19 |
| Stock-Based Compensation to Revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Income Quality | 0.89 | 1.57 | 3.20 | 2.82 | 1.52 |
Currency in USD
